# AOD-9604 Research: Mechanism, Preclinical Evidence, and Clinical Trials

> AOD-9604 mechanism of action: inhibition of acetyl-CoA carboxylase, beta-3 adrenergic receptor upregulation, and six controlled human trials. The complete research record reviewed.

The complete published record — in-vitro mechanism studies from 1983 through 2001, the METAOD human trial program, and the 2025-active osteoarthritis trial.

## hGH Fragment 176-191: The Structural Origin of AOD-9604

Human growth hormone is a 191-amino-acid polypeptide with two distinct functional domains. The N-terminal region drives growth-promoting effects: receptor binding, IGF-1 stimulation, and the anabolic and diabetogenic actions associated with pharmacological hGH. The C-terminal region — residues 176–191 — carries a separable antilipogenic and lipolytic function.

The 1993 paper by Wu and Ng demonstrated that the synthetic C-terminal sequence hGH 177–191 showed antilipogenic activity identical to intact hGH in isolated rat adipose tissue in vitro [1]. The same year, Wijaya and Ng showed that hGH fragment 177–191 reduced both basal and insulin-stimulated glucose uptake in isolated rat adipocytes, with potency exceeding the intact hormone — localizing the antilipogenic functional domain to this C-terminal region [4]. In 1994, Natera, Jiang, and Ng demonstrated reduction of cumulative body-weight gain and decreased adipose tissue mass in obese mice treated chronically with the hGH 177–191 peptide [2].

AOD-9604 is the synthetic analogue of this fragment. It replaces phenylalanine at the original N-terminal position with tyrosine, yielding the identifier Tyr-hGH177–191. The tyrosine substitution was not the site of the antilipogenic activity; it was an N-terminal modification designed to improve peptide stability while preserving function. The [hGH fragment 176-191 structure](/research#hgh-fragment-176-191) — sixteen nodes from residue 176 to 191 — is the subject of every preclinical and clinical study in the AOD-9604 record.

## AOD-9604 Mechanism of Action

AOD-9604 exerts its metabolic effects through at least two documented pathways, both operating at the level of adipocyte fat storage and mobilization.

**Pathway one — inhibition of acetyl-CoA carboxylase:** Bornstein, Ng, Heng, and Wong (1983) established that both hGH and its C-terminal fragment interact with adipocyte and hepatocyte plasma membranes, releasing a second messenger that phosphorylates and inactivates acetyl-CoA carboxylase — the rate-limiting enzyme in fatty acid synthesis [3]. Inactivating this enzyme suppresses de novo lipogenesis: less acetyl-CoA is converted to malonyl-CoA, and fatty acid biosynthesis slows at its first committed step.

**Pathway two — beta-3 adrenergic receptor upregulation:** Heffernan et al. (2001) found that AOD-9604 and hGH both upregulated beta-3 adrenergic receptor (ADRB3) mRNA in obese mice [6]. ADRB3 is expressed predominantly on white and brown adipose tissue; its activation by catecholamines triggers cAMP-mediated phosphorylation of hormone-sensitive lipase, promoting triglyceride breakdown. In beta-3 AR knockout mice, the chronic weight-loss benefit of AOD-9604 treatment was abolished — directly implicating ADRB3 upregulation in the sustained lipolytic response. Acute energy expenditure was partially preserved in knockout animals, suggesting a secondary mechanism (likely the lipogenesis-suppression pathway) contributes to short-term energy balance effects [6].

**What AOD-9604 does not do:** It does not bind the hGH receptor. It does not stimulate IGF-1. In obese ob/ob mice, chronic treatment increased in-vivo fat oxidation and elevated plasma glycerol (a lipolysis index) without inducing hyperglycemia or reducing insulin secretion — contrasting directly with intact hGH, which does induce hyperglycemia in these models [5].

**Glucose transport modulation:** A third effect was documented in vitro: the fragment reduced D[1-14C]-2-deoxyglucose uptake in isolated Zucker obese rat adipocytes at molar concentrations equivalent to hGH, with greater potency than the intact hormone [4]. This reduction in insulin-stimulated glucose uptake into adipocytes was proposed to reduce the substrate available for lipogenesis — a third antilipogenic mechanism operating in parallel with acetyl-CoA carboxylase inhibition.

## Preclinical evidence: rodent models

The preclinical body of evidence spans in-vitro cell assays and in-vivo obese-rodent models. The findings were consistent across model types.

In obese ob/ob mice and Zucker obese rats, chronic treatment with AOD-9604 (or its direct precursor hGH 177–191) reduced body-weight gain, decreased adipose tissue mass, and increased in-vivo fat oxidation compared with untreated obese controls [2][5][7]. Elevated plasma glycerol in treated animals confirmed that lipolysis — the hydrolysis of stored triglycerides — was occurring at a measurably higher rate [5]. No hyperglycemia and no impairment of insulin secretion were observed in any obese rodent model reviewed [5][7].

The beta-3 AR knockout experiment by Heffernan et al. (2001) added mechanistic resolution: by eliminating the beta-3 receptor in a separate mouse line, the long-term weight-loss benefit of AOD-9604 was abolished even though short-term energy expenditure remained partially elevated. This confirms ADRB3 upregulation as the primary driver of the sustained lipolytic effect in chronic treatment, while the immediate lipogenesis-suppression effect operates independently of this receptor [6].

A 2015 rabbit study by Kwon and Park introduced a second research context entirely: intra-articular injection of AOD-9604 at 0.25 mg per week (ultrasound-guided) enhanced cartilage regeneration in a collagenase-induced osteoarthritis model. Combined AOD-9604 plus hyaluronic acid produced significantly lower cartilage degeneration scores and a lameness period of approximately 11 days versus approximately 25 days in the untreated control group. The combination outperformed either agent alone [14]. This finding is the basis for the ongoing NCT07225829 human Phase 2a trial.

## Why was AOD-9604 discontinued?

The pharmaceutical development of AOD-9604 as an obesity drug was discontinued in 2007 after the pivotal Phase IIb trial failed its primary endpoint. The failure was not a safety failure — safety data was the program's strongest result. It was an efficacy failure: at 24 weeks in 536 obese adults, no dose tested (0.25, 0.5, or 1 mg/day oral) produced statistically significant body-mass reduction versus placebo [9].

The non-linear dose-response observed in Phase IIa compounded the problem. At 1 mg/day, a 2.6 kg versus 0.8 kg placebo difference was measured at 12 weeks [8]. At 10 mg/day, the reduction was smaller, not larger. The mechanism for this inverted dose-response was not fully explained in the published literature. When the more rigorous Phase IIb protocol — 24 weeks, larger sample, powered for a predefined efficacy threshold — was applied, the 12-week Phase IIa signal did not replicate to the level required for regulatory approval.

This outcome does not erase the preclinical data or the safety record. It does define the limits of what the evidence establishes: robust in-vitro and rodent-model evidence for the lipolytic mechanism; a Phase IIa signal that did not replicate in the pivotal trial; a clean safety and tolerability record across six trials and approximately 900 participants; and an active intra-articular program continuing in a different indication.

## AOD-9604 Clinical Trials: The METAOD Program

The METAOD program comprised six Phase I and Phase II randomized, double-blind, placebo-controlled trials completed by Metabolic Pharmaceuticals Ltd and enrolling approximately 900 participants in total [9][10].

Phase I trials established the safety profile at escalating doses with no serious adverse events and no dose-limiting toxicities. Phase IIa (12 weeks, approximately 300 obese adults) produced the key efficacy signal: 2.6 kg weight loss versus 0.8 kg placebo at 1 mg/day oral [8]. The non-linear dose-response — with 10 mg/day outperformed by 1 mg/day — was identified at this stage.

The pivotal Phase IIb OPTIONS study enrolled 536 obese adults across multiple sites. Subjects received 0.25 mg, 0.5 mg, or 1 mg oral tablet daily for 24 weeks. The primary endpoint — statistically significant body-mass reduction versus placebo — was not achieved at any dose. Development was halted following this result [9].

The safety data across all six trials was consistent: no serious adverse events attributable to AOD-9604, no treatment-related trial withdrawals, no IGF-1 elevation, no anti-AOD-9604 antibodies, and no disruption to carbohydrate metabolism. The most common adverse event — mild-to-moderate headache — occurred at similar rates in the treatment and placebo arms [10]. Comprehensive preclinical and clinical toxicology, including 6-month rat and 9-month cynomolgus monkey chronic-toxicology panels and genotoxicology assays, found no signals of toxicological or genotoxicological concern [11].

An intra-articular formulation, 4P004, entered human Phase 2a trials for knee osteoarthritis with synovitis (NCT07225829, KL grade 2–4) as of 2025. Results have not yet been published.

For a review of trial-reported outcomes in detail, see [before and after research outcomes](/results). For [AOD-9604 regulatory history and discontinuation](#discontinuation), see above.

## AOD-9604 compared to other lipolytic peptides in the literature

Head-to-head comparisons between AOD-9604 and other lipolytic peptides are limited in the published literature. The distinguishing feature of AOD-9604 in the research record is its selective lipolysis without activation of the IGF-1 axis. Full-length hGH induces both lipolysis and IGF-1-mediated growth effects — and causes hyperglycemia in obese rodent models. CJC-1295 and ipamorelin stimulate endogenous hGH release, which in turn activates IGF-1. AOD-9604 in every model reviewed did not elevate IGF-1 and did not cause hyperglycemia [5][10].

This selectivity was the entire rationale for the METAOD program. The compound's failure to translate that preclinical selectivity into a clinically significant fat-loss outcome in humans is the key finding of the research record — not evidence against the mechanism, but evidence that the magnitude of effect in humans was insufficient for regulatory approval at the doses and duration studied.

## AOD-9604 regulatory history and discontinuation

Developed from the late 1990s by Metabolic Pharmaceuticals Ltd (Melbourne), AOD-9604 progressed through six clinical trials before pharmaceutical development was discontinued in 2007 following the OPTIONS Phase IIb failure [9][12][13]. The compound was reviewed in drug-development surveys in 2004 [12] and 2006 [13] as a peripheral metabolic anti-obesity agent advancing through clinical trials.

Following discontinuation of the pharmaceutical program, Phosphagenics Ltd licensed AOD-9604 in 2009 for transdermal cosmeceutical application (cellulite). No peer-reviewed human efficacy data for the transdermal route was identified in the literature reviewed.

FDA GRAS designation was granted for AOD-9604 as a nutraceutical ingredient for use in foods, beverages, and dietary supplements, confirmed by Moré and Kenley (2014) [11]. WADA classifies the compound under S0 (Non-Approved Substances) — prohibited at all times in competitive sport because it is a discontinued drug candidate with no current approval by any regulatory health authority for human therapeutic use.

---

The AOD-9604 record, reduced to essentials — six human trials catalogued, primary endpoint outcome stated, no clinic and no prescription on the premises.